Skip to content
DataLookout
Menu

NCT04875078

UVA-1 for Treatment of Skin Tightening and Improvement of Hand Function in Scleroderma

StatusCompleted
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 6 versions: 6 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 2, 2026 Show 11 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 14 words
    • Trial status changed: Enrolling by Invitation → Completed
    • Final enrollment: 9 participants (planned 30)
    • Primary completion date changed from estimate of Dec 2025 to Mar 31, 2023
    • Interventions modified
    • Trial arms changed: 2 → 1
    • Study completion date changed from estimate of Dec 2025 to Dec 31, 2024
    • Secondary endpoints: 8 to 5
    • Study description shortened, about 1,083 words
    • Publications: details revised at 11 of 12 entries
  2. Notable Primary and study completion dates: Dec 2024 to Dec 2025v5
  3. Notable Primary completion date: May 2024 to Dec 2024v4
  4. Notable Primary completion date: Aug 2023 to May 2024
    • Trial status: Recruiting to Enrolling by Invitation
    • Study completion date: Dec 2023 to Dec 2024
    • Site details revised
    v3
  5. Notable Primary completion date: Jan 2023 to Aug 2023
    • Study completion date: Aug 2023 to Dec 2023
    v2
  6. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

Hand Mobility in Scleroderma (HAMIS) Score at Treatment 30
Timeframe: After 30 UVA1 treatment sessions (approximately 100 days from baseline)

Secondary (5)

Michigan Hand Outcomes Questionnaire (MHQ) Scores
Modified Rodnan Skin Score (mRSS) of the Hands and Fingers
Skindex-16 Scores
PROMIS Physical Function (PROMIS-PF) Score
Hand Disability in Systemic Sclerosis-Digital Ulcers (HDISS-DU) Score

Arms and interventions

All Study ParticipantsExperimental

All participants received both intervention conditions in a randomized, split-person (intra-patient) design. One hand was randomized to receive UVA1 phototherapy, and the contralateral hand served as the control and was covered with a UV-blocking glove during UVA1 treatment sessions. Treatment-hand assignment was determined using a random number generator.

Devices: UVA-1 Phototherapy

Other: UV-Blocking Glove

Sites

1 site in 1 country

  • University of Utah MidValley DermatologyMurray, Utah, United States